US Keratoconus Treatment Market

ID: MRFR/HC/11791-HCR 100 Pages Satyendra Maurya Last Updated: September 15, 2026
US Keratoconus Treatment Market Research Report By Keratoconus Type (Corneal Hydrops, Forme Fruste Keratoconus, Posterior Keratoconus, Keratoglobus, Pellucid Marginal Degeneration), By Treatment Type (Lenses, Surgery, Corneal Cross-Linking) and By End User (Eye Clinics, Hospitals) - Growth & Industry Forecast 2025 To 2035
US Keratoconus Treatment Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)3.35%
2024 Market Size$ 67.2 Million
2025 Market Size$ 69.3 Million
2035 Market Size$ 96.6 Million
Key Players
Johnson & Johnson
Bausch + Lomb
Alcon
Abbott Laboratories
CooperVision
Carl Zeiss AG
Opportunities
  • Rising Prevalence of Keratoconus
  • Technological Innovations in Treatment
  • Growing Demand for Personalized Medicine
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Healthcare, BY Treatment Type (USD Million)
      1. 4.1.1 Corneal Cross-Linking
      2. 4.1.2 Intacs
      3. 4.1.3 Scleral Lenses
      4. 4.1.4 Keratoplasty
      5. 4.1.5 Pharmaceuticals
    2. 4.2 Healthcare, BY Patient Demographics (USD Million)
      1. 4.2.1 Age Group
      2. 4.2.2 Gender
      3. 4.2.3 Socioeconomic Status
      4. 4.2.4 Geographic Distribution
    3. 4.3 Healthcare, BY Distribution Channel (USD Million)
      1. 4.3.1 Hospitals
      2. 4.3.2 Specialty Clinics
      3. 4.3.3 Online Pharmacies
      4. 4.3.4 Optometry Practices
    4. 4.4 Healthcare, BY End User (USD Million)
      1. 4.4.1 Ophthalmologists
      2. 4.4.2 Optometrists
      3. 4.4.3 Healthcare Institutions
      4. 4.4.4 Research Organizations
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Healthcare
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Johnson & Johnson (US)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Bausch + Lomb (US)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Alcon (US)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Abbott Laboratories (US)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 CooperVision (US)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Carl Zeiss AG (DE)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Avedro (US)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Eyevance Pharmaceuticals (US)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
      9. 5.2.9 Orbis International (US)
        1. 5.2.9.1 Financial Overview
        2. 5.2.9.2 Products Offered
        3. 5.2.9.3 Key Developments
        4. 5.2.9.4 SWOT Analysis
        5. 5.2.9.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 US MARKET ANALYSIS BY TREATMENT TYPE
    3. 6.3 US MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    4. 6.4 US MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    5. 6.5 US MARKET ANALYSIS BY END USER
    6. 6.6 KEY BUYING CRITERIA OF HEALTHCARE
    7. 6.7 RESEARCH PROCESS OF MRFR
    8. 6.8 DRO ANALYSIS OF HEALTHCARE
    9. 6.9 DRIVERS IMPACT ANALYSIS: HEALTHCARE
    10. 6.10 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
    11. 6.11 SUPPLY / VALUE CHAIN: HEALTHCARE
    12. 6.12 HEALTHCARE, BY TREATMENT TYPE, 2024 (% SHARE)
    13. 6.13 HEALTHCARE, BY TREATMENT TYPE, 2024 TO 2035 (USD Million)
    14. 6.14 HEALTHCARE, BY PATIENT DEMOGRAPHICS, 2024 (% SHARE)
    15. 6.15 HEALTHCARE, BY PATIENT DEMOGRAPHICS, 2024 TO 2035 (USD Million)
    16. 6.16 HEALTHCARE, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
    17. 6.17 HEALTHCARE, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Million)
    18. 6.18 HEALTHCARE, BY END USER, 2024 (% SHARE)
    19. 6.19 HEALTHCARE, BY END USER, 2024 TO 2035 (USD Million)
    20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY TREATMENT TYPE, 2026-2035 (USD Million)
      2. 7.2.2 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Million)
      3. 7.2.3 BY DISTRIBUTION CHANNEL, 2026-2035 (USD Million)
      4. 7.2.4 BY END USER, 2026-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

US Keratoconus Treatment Market Segmentation

US Keratoconus Treatment Market By Treatment Type (USD Million, 2026-2035)

  • Corneal Cross-Linking
  • Intacs
  • Scleral Lenses
  • Keratoplasty
  • US Keratoconus Treatment Markets

US Keratoconus Treatment Market By Patient Demographics (USD Million, 2026-2035)

  • Age Group
  • Gender
  • Socioeconomic Status
  • Geographic Distribution

US Keratoconus Treatment Market By Distribution Channel (USD Million, 2026-2035)

  • Hospitals
  • Specialty Clinics
  • Online Pharmacies
  • Optometry Practices

US Keratoconus Treatment Market By End User (USD Million, 2026-2035)

  • Ophthalmologists
  • Optometrists
  • US Keratoconus Treatment Market Institutions
  • Research Organizations
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.